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Abstract
Background—Disordered thyroid hormone transport, due to mutations in monocarboxylate 
transporter 8 (MCT8), is characterized by intellectual and motor disability due to cerebral 
hypothyroidism and chronic peripheral thyrotoxicosis. Phenotypic characteristics and natural 
history of MCT8 deficiency have not been systematically evaluated.
Methods—In this international, multicentre, study, retrospective data (2003 to 2019) from 
patients with MCT8 deficiency followed in 47 centres, was analysed. Our primary objectives were 
to determine neurocognitive outcomes and overall survival. We also assessed clinical parameters, 
including anthropometric characteristics, biochemical markers and neuroimaging findings.
Results—151 subjects with 73 different MCT8 mutations were included. 21·2% (32/151) of 
patients died at a median age of 10·5 years (range 1·6-71·0), with main causes of mortality being 
pulmonary infection (18·8%) and sudden (cardiac) death (18·8%). Survival differed significantly 
between individuals who attained head control or not (log-rank test: p=0·002; hazard ratio 3·99 
95%CI 1·89-8·76). The limited motor and cognitive abilities of patients did not improve with age. 
T3 concentrations were elevated in 95·1% (96/101) and total T4 concentrations were reduced in 
89·5% (94/105) of patients. 71·1% (59/83) patients were underweight (<-2SD). Cardiovascular 
abnormalities were frequent, with 53·2% (25/47) of patients exhibiting elevated systolic blood 
pressure, and 75·6% (34/45) of patients having premature atrial contractions and 31·3% (20/60) 
having resting tachycardia.
Interpretation—Our description of characteristics and natural history of MCT8 deficiency in 
a large patient cohort reveals poor survival with a high prevalence of treatable underlying risk 
factors and provides knowledge which informs clinical management and future evaluation of 
therapies.
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Thyroid hormones are crucial for normal physiological processes, particularly 
neurodevelopment, and regulation of basal metabolic rate, throughout life (1, 2). 
Intracellular bioavailability of thyroid hormones is governed by membrane transporter 
proteins that facilitate their cellular entry (3). Monocarboxylate transporter 8 (MCT8) is 
a specific thyroid hormone transporter that is crucial for transport of tri-iodothyronine (T3) 
and thyroxine (T4) in several tissues, including the brain (4–8). Mutations in the gene 
encoding MCT8 (SLC16A2 on chromosome Xq13.2) cause MCT8 deficiency, also known 
as Allan-Herndon-Dudley syndrome (AHDS), a debilitating disorder with an estimated 
prevalence of 1 in 70 000 male individuals (9–11).
MCT8 deficiency is characterized by profound neurodevelopmental delay and a wide range 
of severe clinical sequelae secondary to chronic peripheral thyrotoxicosis which cannot be 
effectively treated with conventional (anti)thyroid drugs (3, 10, 11). In 2019, a clinical 
trial showed that treatment with triiodothyroacetic acid (Triac) ameliorates key features 
of peripheral thyrotoxicosis and might improve neurocognitive outcomes if treatment is 
commenced early in life (12).
Robust, comprehensive data regarding the phenotypic characteristics and natural history of 
patients with MCT8 deficiency are lacking, as the phenotype has only been recorded in 
single case reports or small case series with related patients [e.g. (13, 14)]. Furthermore, 
these reports used differing clinical methods precluding consistent assessments, and merely 
focused on the neurological phenotype, neglecting the peripheral clinical features of the 
disorder (3, 14). Data on survival and neurodevelopmental outcomes in this disorder are 
not known. The lack of consistent quantitative knowledge of the natural history and the 
phenotypic spectrum of MCT8 deficiency hampers early diagnosis and uniform clinical 
management including the evaluation of a disease-modifying therapy.
Given the paucity of recorded data and with access to a large patient cohort via an 
international collaborative network for this rare disorder, we have sought to provide 
comprehensive and uniform phenotypic characterization of MCT8 deficiency using clinical, 
radiological, and biochemical data.
Methods
Study design and participants
This international study was initiated on 14 October 2014 by founding a consortium of 
centres where patients with MCT8 deficiency were followed up.
The key inclusion criterion was genetically confirmed MCT8 deficiency. Additionally, data 
on first-degree and second-degree male relatives with clinical MCT8 deficiency (when 
genetic testing was not available at that time) were included. There were no exclusion 
criteria. Our cohort consisted of patients that had been enrolled in the international, 
multicentre Triac Trial [NCT02060474, (12)], patients who participated in the named patient 
program for Triac treatment and patients for whom Erasmus MC fulfilled a consultancy 
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role. A subgroup of participants has been reported before with available individual case 
descriptions (n=47), or has been reported on aggregated level (n=46, (12)) (figure S2A). For 
such patients, updated and exhaustive data were collected. For analysis of serum thyroid 
function tests, only patients whose measurements were performed in the central laboratory 
of the Erasmus MC were considered to avoid inter-assay variation. For in-depth clinical and 
biochemical phenotyping only those patients were enrolled that either participated in the 
Triac Trial (12) or in the named patient program to ensure data had been captured by trained 
personnel and according to standard operating procedures.
Ethical considerations
This study conforms to the Declaration of Helsinki, Good Clinical Practice guidelines and 
was evaluated and approved by the appropriate local institutional review boards or ethics 
committees. However, for the retrospective analysis of existing datasets of patients in routine 
clinical care, the majority of centres did not require additional specific institutional review 
board approval. For other centres, studies were either ethically approved or the ethics 
committee provided a waiver for approval. Informed consent was obtained from the parents 
or legal representatives of all enrolled patients, unless the relevant institutional review 
board and/or local regulations had authorized the use of anonymised patient data without 
additional consent.
Procedures
An overview of study assessments and investigations is provided in Figure s1 and in the 
Supplementary Methods.
Outcomes
Our primary objective was to analyse the overall survival of patients with MCT8 deficiency 
and document causes of death. We also compared survival between patients who did or did 
not attain full head control and between patients who were underweight or not.
Other key objectives were to document neurocognitive function using uniform criteria 
and assess their relationship to biological age as a measure of disease progression and 
developmental outcome and to describe the occurrence of extra-neurological features.
Statistical analysis
We summarised continuous variables as mean and standard deviation (SD), or median and 
range. We established overall survival and compared patients with and without full head 
control with log-rank analysis. Survival was defined as the age at last date known alive. 
Correlations between biological age and scores on different neuropsychological assessments 
were explored using linear regression. For these analyses, we excluded patients with a less 
severe neurocognitive phenotype, defined as individuals that attained at least two of the 
following developmental milestones: talking in simple words, achieving head control, sitting 
independently, and/or walking with assistance. All statistical tests were two-sided, and p 
values of less than 0·05 were considered statistically significant. Statistical analyses were 
performed using GraphPad Prism, version 6 (GraphPad, La Jolla, CA, USA).
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Role of funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
In 47 centers, 151 patients of 22 different nationalities (8 ethnicities) were enrolled between 
October 14th 2014 and January 17th 2020 (figure s1). In 106 cases serum thyroid function 
tests had been measured in the central laboratory, and 86 had been checked according to 
standardised protocols for in-depth phenotyping at a median age of 4·8 years (interquartile 
range [IQR] 1·9-9·8, range 0·4-66·8) (figure s1).
The demographics and characteristics of the enrolled patients are summarised in table s1. In 
the 151 enrolled cases, 73 different underlying MCT8 mutations were identified, of which 
38 had not been reported before (figure s2B). A total of 17 mutations were identified in at 
least two unrelated families. All 35 missense mutations were located in the transmembrane 
helices (figure s3). The median age at diagnosis was 24·0 months (range: 0·0-744·0) (figure 
1A), but the median age at onset of first symptoms was 4·0 months (range: 0·0-13·0) (figure 
1A). Consequently, the median time to diagnosis was 18·0 months (IQR 7·8-63·0, range 
0·0-738·0). The most frequently reported initial concerns that prompted medical evaluation 
were gross developmental delay (78·6%), hypotonia (39·8%), feeding problems (8·2%), and 
poor weight gain (7·1%) (figure 1B).
32 (21·2%) patients had died at a median age of 10·5 years (IQR 5·3-18·8, range 1·6-71·0). 
The main causes of death were pulmonary infections (18·8%), sudden (cardiac) death 
(18·8%), and aspiration pneumonia (9·4%) (figure 1C). In 15 (46·9 %) of 32 deceased 
subjects the cause of death was unclear and postmortem examinations had not been 
performed. The median overall survival was 35·0 years (95% CI 8·3-61·7; figure 1D). 
The 10-, 18-, and 60-year survival probabilities were 85% (95% CI 78·0-92·0), 69·8% 
(58·2-80·3), and 34·8% (10·2-59·3), respectively. Patients attaining full head control had 
a median survival of 63·0 years (95% CI 40·6-85·4) compared with patients who did not 
attain head control who had a median survival of 30·3 years (15·5-45·0; HR 3·99, 95% CI 
1·89-8·76, p=0·002; figure 1E). Patients having underweight had a median survival of 30·3 
years compared with patients not having underweight who had a median survival of 71·0 
years (HR 3·83, 95% CI 1·05-13·92, p=0·04; figure 1F).
The prevalence of specific neurological features in patients included in the in-depth 
phenotyped cohort (N=86, median age 4·8 years, IQR 1·9-9·8, range 0·4-66·8) is reported 
in table 1 and figure 2, and neurological sequelae are summarized in figure s4 and figure 
s5. All patients had moderate-to-severe intellectual disability with a severe delay in motor 
and language development (table s2). Only 6 (7·7%) patients achieved independent sitting 
and were less severely affected than the other patients (figure 2A and B). The median score 
on the Gross Motor Function Measure 88 (15) did not exceed 10% of the total score that 
should be obtained by healthy 4-year old children (figure 2B, table s2). Among 30 subjects 
that had been evaluated at a median age of 7·4 years (range 0·4-66·8) with the Bayley Scales 
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of Infant Development III (16), the median developmental age was well-below 12 months 
on all tested sub-domains (figure 2C and D, figure s6A-C, table s2). When analyzing data 
from just severely affected patients, none of the scores in any of the developmental domains 
improved with age, with fine motor skills even showing regression (figure 2E and F, figure 
s6D-G).
Pregnancy and delivery were unremarkable in the majority of cases, with most children 
having good Apgar scores, normal birth weight at term and head circumference (table 1). At 
first presentation, most patients had global hypotonia with a pronounced head-lag on vertical 
suspension and upper trunk slipping through. Typically, by the end of the first year, dystonic 
posturing of the limbs and neck were noted. Exaggerated deep tendon reflexes were present 
in 80·3% (57/71) of cases, and 90·5% (67/74) of patients developed hypertonia in wrists, 
knees or heels with age attributed to dystonia and spasticity. Primitive reflexes remained 
present in 91·1% (51/56) cases, with a positive tonic neck reflex (81·0%) and glabellar 
sign (80·0%) being most prevalent, irrespective of patient age. Electro-encephalogram 
(EEG)-confirmed seizures were observed in 15 (23·1%) of 65 patients, and mostly involved 
generalized, absence-like episodes without a clear motor component.
MRI scans of the brain were available in 13 patients, performed at a median age of 8·0 
months (range: 5·0-187·0), with 8 patients having at least one follow-up scan available 
(table 1, figure s4, table s3). The most consistent finding was a global delay in myelination, 
evidenced by diffuse residual hyperintense white matter in specific brain regions on T2-
weighted images. Myelination improved with age, but had not fully normalized in the oldest 
patient (15 years) with available data. Most cases showed diffuse cortical and subcortical 
atrophy with dilatation of the ventricles, widening of the subarachnoid spaces demonstrated 
by prominence of the supra- and infra-tentorial sulci. In 6 (85·7%) of 7 patients magnetic 
resonance spectroscopy (MRS) showed an increased choline peak and a decreased N-acetyl 
aspartate (NAA) peak, which is compatible with aberrant myelination and general atrophy. 
These neuroradiological findings were supported by postmortem findings in the brain of a 
deceased 8-year old patient, showing global reduction of brain volume and diffuse reduction 
in myelination (see supplementary results).
Serum thyroid function tests were available in 106 treatment-naïve patients at a median 
age of 5·3 years (IQR 2·1-11·0, range 0·4-66·8). Serum TSH concentrations were within 
the normal range in 93 (88·6 %) of 105 patients (figure 3A). Serum free and total T4 
concentrations were below the age-specific lower limit in 94 (88·7 %) of 106 and 94 
(89·5%) of 105 patients, respectively (figure 3B and figure s7A and s7B). Mean serum T3 
concentrations exceeded the age-specific upper limit in 96 (95·1%) of 101 patients (figure 
3C), which resulted in a pronounced increase in the T3/T4 ratio (figure s7C). Reverse 
T3 (rT3) concentrations were decreased in 76 (90·5%) of 84 patients (figure s7D), with a 
concomitant increase in the T3/rT3 ratio (figure s7E). In 3 out of 7 subjects TRH-stimulation 
tests showed an inadequate TSH response. In 7 (87·5%) out of 8 subjects in whom T4-based 
neonatal screening results were available, total T4 concentrations were below the 20th 
percentile (figure 3D). Serum total T4 concentrations were significantly less reduced in 
patients with less severe versus those with a severe neurocognitive phenotype (figure s7F). 
Serum T3 concentrations were not significantly different between these groups (figure s7G). 
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Consequently, the T3/T4 ratio, a marker of thyroid hormone metabolism in peripheral 
tissues, was significantly lower in patients with a less severe phenotype (figure s7G).
In-depth phenotyping of peripheral clinical features was undertaken in 86 patients (median 
age 4·8 years, IQR 1·9-9·8, range 0·4-66·8) and the main findings are summarised in table 
2 and table s4. Body weight for age showed progressive deterioration over time, with 59 
(71·1%) of 83 patients being severely underweight (<-2SD) (figure 3E, table 2). 27 (35·5%) 
of 76 patients were tube fed, although impaired swallowing function was reported in 55 
(71·4%) of 77 patients. Body height for age also deteriorated with age (figure 3F). Delayed 
sexual maturation was present in 5 (26·3%) patients (figure s8A-D). Among patients over 8 
years of age, bone mineral density (BMD) was below the 5th percentile, but bone turnover 
markers were generally within the low-normal range (figure s9A-D).
The mean resting heart rate measured by electrocardiography was 110 (±20) beats per 
minute, with 20 (31·3%) of 64 patients exceeding the 90th percentile of heart rate (figure 
3G) (17). Systolic blood pressure exceeded the 90th percentile in 25 (53·2%) of 47 patients 
whereas the diastolic blood pressure exceeded the 90th percentile in 17 (36·2%) of 47 
patients (figure 3H) (18, 19). Detailed cardiovascular assessment was available in 50 
patients. At the time of evaluation, 47 (94%) of 50 patients reportedly had no cardiovascular 
abnormalities and were not receiving any treatment. 3 (6·0%) of 50 patients had second-
degree atrioventricular block (Mobitz I: 1; Mobitz II: 2) and 6 (12·0%) of 50 patients had 
(incomplete) right bundle branch block. In addition, corrected QT interval (QTc) was above 
the 98th percentile in three out of 39 (7·7%) patients (table 2, figure s10A). Even though 
most patients were completely immobile, 24h ambulatory cardiac monitoring showed a high 
resting heart rate (103±13 beats per minute) with frequent episodes of tachycardia and 
premature atrial or ventricular contractions (figure 3I, table s4). One childhood patient had 
an episode of atrial fibrillation and another had non-sustained ventricular tachycardia (table 
2). Cardiac echocardiography studies performed in 26 patients revealed dilated aortic root 
(>+2SD for age, range 2·0-3·4 SD) in 7 (26·9%) patients, and relatively small left ventricular 
wall dimensions (figure s10B).
Serum concentrations of sex hormone binding globulin were elevated in 69 (88·5%) of 78 
patients (figure 3J), whereas total cholesterol concentrations were in the low normal range 
(figure s11A). Serum alanine aminotransferase, aspartate aminotransferase, and gamma-
glutamyl transferase concentrations were mildly elevated in a substantial proportion of 
patients (table 2, figure s11B-D), whereas ammonia concentrations were mostly normal 
(figure s11E). Of note, two patients reportedly had an episode of hepatic dysfunction 
following a (viral) infection.
43 (84·3%) of 51 patients had low muscle mass. Creatinine concentrations in serum were 
within the low-normal range for age (figure 3K). Serum creatine kinase concentrations were 
mostly low-normal (figure 3L), with some exceptions in patients with recent seizures or 
severe dystonic episodes. Serum lactate concentrations were slightly increased in 3 (27·3%) 
of 11 patients (Figure s11F).
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Gastroesophageal reflux disease was present in 79·2% (38/48) of patients and this often 
required pharmacological intervention. Spontaneous gastrointestinal bleeding was reported 
in 2 patients and was the cause of death in one of them. Constipation was present in 62·3% 
(37/63) of patients. 29 (69·1%) of 42 patients had recurrent (pulmonary) infections (table 2).
Discussion
To our knowledge, this international, multicentre, retrospective study is unique, representing 
quantitative evaluation of the natural history of MCT8 deficiency in the largest cohort 
of patients with this disorder. We have documented key clinical features together with 
biochemical and radiological correlates as well as outcomes in this rare but potentially 
treatable condition. Our findings will facilitate accurate diagnosis, guide management, and 
inform conduct of future therapeutic intervention trials.
A principal finding is that overall survival of patients with MCT8 deficiency is greatly 
diminished, with an overall median life expectancy of 30 years. Stratification of analyses 
revealed that patients who attain full head control are more likely to survive longer than 
those who do not. Accordingly, attaining full head control, as a marker of improved 
neurodevelopment, could be a relevant endpoint for future therapeutic trials in MCT8 
deficiency.
The most common cause of death was pneumonia, caused either by aspiration or by 
infections. Aspiration, due to impaired swallowing function, is frequently observed in 
patients with MCT8 deficiency, and this could be mitigated by tube feeding. However, a 
substantial number of patients that exhibited swallowing problems were not tube fed and 
thus remained at risk for aspiration. With underweight being strongly linked to survival, 
tube feeding can prevent adverse clinical sequelae and potentially improve survival (20). The 
second major cause of mortality was sudden death. Although its aetiology remains unclear, 
available data points to a cardiac cause, with the high prevalence of premature atrial and 
ventricular contractions, which are uncommon in healthy individuals especially in childhood 
(21–25). We also observed non-sustained ventricular tachycardia and QTc prolongation 
in some patients, with both considered risk factors for sudden cardiac death. Moreover, 
a substantial proportion of patients exhibited systolic hypertension and/or tachycardia 
and had several structural and electrophysiological cardiac changes that have been linked 
to these traits. As the vast majority (94·0%) of patients reportedly had no history of 
cardiac problems, these cardiovascular abnormalities likely remain clinically undiagnosed 
in this population. This observation calls for inclusion of cardiovascular assessment in 
the management of this disorder. With loss of body weight and many cardiovascular 
abnormalities being attributable to chronic thyrotoxicosis, reduction in circulating T3 
concentrations in patients could represent effective treatment for these aspects of the 
disorder. Indeed, in a recent clinical trial, treatment with the thyroid hormone analogue 
Triac efficiently reduced serum T3 concentrations and improved key clinical features such as 
loss of body weight and reversal of abnormal cardiovascular parameters in MCT8 deficiency 
(12).
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The current study also identified several other clinical features that require treatment or 
close followup, of which gastro-esophageal reflux disease, scoliosis, hip luxation, and 
constipation have the highest prevalence. The presence of mildly elevated aminotransferases 
and the occurrence of transient hepatic failure in at least three reported cases following a 
viral infection [this report and (11)], suggest that drugs with hepatotoxic side effects (e.g. 
anti-epileptic drugs as frequently used in this population) should be used with extra caution.
Our comprehensive documentation of neurological sequelae in patients with MCT8 
deficiency revealed that the combination of global hypotonia, hypertonia due to dystonia and 
spasticity and persistence of primitive reflexes was present in up to 90% of patients. Delayed 
myelination on MRI was consistent with other studies (14, 26, 27). Taken together, these 
clinical and neuroimaging characteristics may facilitate early diagnosis of MCT8 deficiency 
and in discriminating this entity from other neurodevelopmental disorders.
Our study highlights major delay in diagnosis of this disorder, with a minority of cases 
being identified in the first year of life. This is mainly attributable to the non-specific 
initial clinical features with lack of awareness of the specific characteristics of this disorder 
among clinicians. Having documented that circulating T3 concentrations are elevated in 
patients below one year of age, the combination of clinical and radiological features with 
measurement of serum T3 concentrations may constitute a key clue for early diagnosis. 
The low T4 concentrations measured in patients with MCT8 deficiency in the neonatal 
screening indicates the potential to diagnose MCT8 deficiency in newborns, perhaps with a 
modification of the current neonatal screening strategy. The importance of early diagnosis is 
supported by preclinical studies in which Triac completely prevented abnormal neurological 
development in animal models of MCT8 deficiency when administrated at birth (28). A 
future phase 2 clinical trial will investigate the effects of Triac on neurodevelopment, with 
treatment being commenced at a very young age (NCT02396459).
This study has limitations inherent to its retrospective design. However, MCT8 deficiency 
is a rare disorder with surviving patients being located throughout the world such that 
retrospective analysis of available clinical data was the most suitable way to increase our 
understanding of this disorder. In general, such study design is prone to collection of an 
incomplete dataset, subjective evaluation of patients with variable followup. However, in this 
study, data in the majority of cases had been collected uniformly during baseline assessment 
of patients wither participating in the Triac Trial or in named patient treatment programs, 
providing an unique opportunity for systematic cross-sectional evaluation of key clinical 
outcomes. Although selection bias cannot be excluded, our study included a substantial 
proportion of currently diagnosed patients.
In summary, this study provides a comprehensive and structured in-depth characterisation 
of the phenotype of MCT8 deficiency. The current study first reports poor survival in 
this disorder, with 30% of patients dying in childhood. Having identified pulmonary 
infection and sudden death (our data suggests cardiac arrhythmia as underlying basis) 
as the major causes of mortality, timely intervention with Triac therapy may ameliorate 
the poor prognosis in this disease. Furthermore, our finding that survival is particularly 
poor in patients with impaired neurological development (head control), provides a basis 
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for therapeutic intervention targeted at this subgroup. Our findings underscore the need 
for a multidisciplinary approach in the management and follow-up of patients with 
MCT8 deficiency. In addition, our observations represent an unique, quantitative dataset 
of the natural history of this disorder which may serve as a historical control for future 
interventional studies in this rare disorder, for which a biological control group is often 
deemed not feasible. Accordingly, we suggest that this study enhances our understanding 
of the clinical sequelae and longterm outcome of MCT8 deficiency and also facilitates the 
diagnosis and management of this disorder.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel A graphically presents the mean ± SEM (black lines) age at onset of symptoms 
and panel B the age at time of diagnosis. Grey dots represent measurements in individual 
patients. Panel C shows the causes of death in patient with MCT8 deficiency. HR: hazard 
ratio. Panel D shows the overall survival based on age at last follow-up (Kaplan-Meier 
estimates). Panel E shows the Kaplan-Meier estimates of MCT8-specific survival in patients 
who attained head control (red line) versus those who did not (blue line) and panel F those 
in patients with (blue line) versus without (red line) underweight.
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Panel A shows the prevalence of clinical, radiological and developmental key features in 
MCT8 deficiency. Bars indicate the proportion of patients presenting the indicated feature 
at first presentation. Panel B represents the gross motor function development in patients 
with MCT8 deficiency measured by the Gross Motor Function Measure (GMFM) 88 (15). A 
100% score indicates the level of development that is achieved by a healthy 4-year old child. 
Panel C shows the development of expressive language and panel D the development of 
receptive language, measured by the respective sub-domains of the Bayley Scales of Infant 
Groeneweg et al. Page 16









































Development (BSID) III (16). Scores are expressed as developmental age in months. Blue 
dots indicate measurements in individual patients and black lines indicate the mean ± SEM 
score. Panel E shows the relation between GMFM 88 score and panel F the developmental 
age on the sub-domain expressive language of the BSID III versus the chronological age 
using linear regression (the 95% CI is displayed as blue dotted lines). Only severely affected 
patients were considered in panel E and F. Linear regression was used to plot the trend and 
the 95% confidence intervals (blue lines). Patients harboring the same genetic mutation are 
displayed in the same color: p.F230del (green), c.651-652+20del (blue), G564R (purple), 
p.A565fs566X (pink), and R271H (orange). Unique mutations are colored in grey.
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Mean ± SEM (black lines) serum concentrations of thyroid stimulating hormone (TSH) 
(panel A) and free T4 (panel B). Panel C presents the serum total T3 concentrations 
versus age. Panel D shows the available results on total T4 measurements during neonatal 
screening expressed in SDs. Blue dots represent measurements in individual patients and 
grey areas the normal range. Panel E shows the natural course of bodyweight change 
in patients with MCT8 deficiency. Blue dots represent available historical bodyweight 
measurements in untreated patients. Non-linear (third order) polynomial regression was 
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used to plot the trend with its 95% error band. Similarly, panel F shows the natural course 
of body height. Panel G shows the resting heart rate by age. Normal range in healthy 
children is derived from (17). Panel H shows the mean ± SEM diastolic and systolic 
blood pressure. The orange line represents the threshold for classification as elevated blood 
pressure and the red line the threshold of hypertension, as defined by the guidelines from 
the American Academy of Pediatrics (18) and the American College of Cardiology and 
American Heart Association (19). Panel I shows the mean ± SEM (black lines) occurrence 
of indicated features during 24h cardiac monitoring in 45 individuals. Serum concentration 
of sex hormone binding globulin (SHBG) (panel J), creatinine (panel K), and creatine 
kinase (panel L) are expressed relative to the age-specific lower (panel K) or upper (panel 
J and L) limit of the normal range. Abbreviations: TSH, thyroid stimulating hormone; 
T4, thyroxine; T3, triiodothyronine; PACs, premature atrial contractions; PVCs premature 
ventricular contractions; CK, creatine kinase; SHBG, sex hormone binding globulin; LL, 
lower limit; UL, upper limit. The absolute mean values of all parameters are summarized in 
table s4.
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Table 1
In depth phenotyping of neurodevelopmental features
N=86
Age at assessment (years) 4·8 (0·44-66·8)
Perinatal features
    Pregnancy duration (weeks) 40·0 (32·0-42·3)
    Apgar scores >8 after 5 min (n=16) 15 (93·8)
    Term birth weight (grams) 3584 (±517)
    Microcephaly (<3th centile) at birth (n=11) 2 (18·2)
Neurological examination
    Hypotonia (n=72) 72 (100%)
    Primitive reflexes (>1 present) (n=56) 51 (91·1%)
        Tonic neck reflex (n=21) 17 (81·0%)
        Glabellar sign (n=55) 44 (80·0%)
        Startle response (n=25) 17 (68·0%)
    Scoliosis (>8 years) (n=17) 15 (88·2%)
    Muscle hypoplasia (n=51) 43 (84·3%)
    Dystonia (n=69) 57 (82·6%)
    Spasticity (n=71) 57 (80·3%)
    Urinary / faecal incontinence (>4 years) (n=41) 33 (80·5%)
    Feeding problems (n=77) 55 (71·4%)
    Hip dislocation (>8 years, n=15) 10 (66·7%)
    Plantar extension response (Babinski sign, n=57) 38 (66·7%)
    Delayed evoked potentials (<6 months, n=6)* 3 (50·0%)
    Sleep problems (n=51) 20 (39·2%)
    Tube feeding (n=76) 27 (35·5%)
    Strabismus (n=54) 19 (35·2%)
    Microcephaly (<3th centile) (n=59) 19 (32·2%)
    Nystagmus (n=49) 13 (26·5%)
    Extrapyramidal signs (other) (n=28) 7 (25·0%)
    Seizures (EEG proven) (n=65) 15 (23·1%)
    Apneusis (n=32) 7 (21·9%)
    Abnormal hearing (n=44) 1 (2·3%)
    Delayed evoked potentials (>1 year, n=3) 0 (0·0%)
Development
    Head control (n=77) 19 (24·7%)
    Speech (at least 1 word) (n=76) 5 (6·6%)
    Independent sitting (n=78) 6 (7·7%)
    Independent walking (n=77) 4 (5·2%)
MRI/MRS characteristics *
    Normal global anatomy (n=13) 13 (100%)
    Delayed myelination (n=13) 13 (100%)
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N=86
    Reduced cerebral white matter volume (n=13) 13 (100%)
    Periventricular white matter lessions (n=10) 10 (100%)
    Prominent supratentorial ventricular system (n=13) 13 (100%)
    Prominent peripheral liquor spaces (n=13) 13 (100%)
    Low NAA peak (n=7) 6 (85·7%)
    High choline peak (n=7) 6 (85·7%)
Data are median (range), n (%), or mean (±SD). Systematic deep phenotyping of neurological phenotype in 86 eligible patients. Median age at last 
available MRI scan: 18·0 months, range 5·0-187·0); MRS was available in 7 cases. Details are provided in table s2.
*
In particular the brainstem-evoked response audiometry was abnormal in children < 1 year of age and showed prolongation of the I-V interval.









































Groeneweg et al. Page 22
Table 2
In depth phenotyping of peripheral features
Characteristic N=106
Serum thyroid function tests
Age at measurement (years) 5·3 (0·4-66·8)
Elevated T3 concentrations (n=101) 96 (95·1%)
Reduced free T4 concentrations (n=106) 94 (88·7%)
Deep phenotyping N=86
Age at assessment (years) 4·8 (0·44-66·8)
Biochemical measurements *
    Elevated sex hormone binding globulin (n=78) 69 (88·5%)
    Elevated alanine aminotransferase (n=65) 30 (46·2%)
    Reduced creatinine (n=79) 22 (27·8%)
    Elevated lactate (n=11) 3 (27·3%)
    Reduced total cholesterol (n=65) 12 (18·5%)
    Elevated aspartate aminotransferase (n=56) 11 (19·6%)
    Elevated creatine kinase (n=79) 3 (3·8%)
Clinical features
    Low bone mineral density (>8 years, n=5) 5 (100%)
    Hypotrophic musculature (n=51) 43 (84·3%)
    Gastro-esophageal reflux disease (n=48) 38 (79·2%)
    Premature atrial complexes (n=45) 34 (75·6%)
    Recurrent (pulmonary) infections (n=42) 29 (69·0%)
    Underweight (<-2 SD, n=83) 59 (71·1%)
    Constipation (n=63) 37 (58·7%)
    Elevated systolic blood pressure 
¶
 (n=47) 25 (53·2%)
    Increased perspiration (n=60) 29 (48·3%)
    Short stature (<-2 SD, n=67) 27 (40·3%)
    Premature ventricular complexes (n=45) 19 (42·2%)
    Tachycardia in rest 
†
 (n=64) 20 (31·3%)
    Aortic root dilatation (n=26) 7 (26·9%)
    Elevated diastolic blood pressure 
¶
 (n=47) 17 (36·2%)
    Delayed sexual maturation (>8 years, n=19) 5 (26·3%)
    Cardiac conduction abnormalities 
‡
 (n=50) 9 (18·0%)
    Cryptorchidism (n=49) 9 (18·4%)
    Prolonged QTc interval (39) 3 (7·7%)
    Supraventricular tachycardia (n=48) 2 (4·2%)
    (Non-sustained) ventricular tachycardia (n=48) 2 (4·2%)
    Atrial fibrillation (n=48) 1 (2·1%)
Data are median (range), or n (%). Systematic deep phenotyping of the peripheral phenotype. Please note that most parameters have not been 
captured in all patients. All absolute and relative values are provided in table s4.
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*
Reduced and elevated indicated concentrations below or above the normal range (2.5-97.5 centile in the healthy population).
†
Tachycardia was defined as a resting heart rate above the 90th percentile for the corresponding age, with cut-offs described by Fleming and 
colleagues (17).
‡
Three out of 50 patients (5·5%) had a second degree atrioventricular block (Mobitz I:1; Mobitz II:2) and 6 out of 50 patients (12·0%) had an 
(incomplete) right bundle branch block and 1 patient (2·0%) had a left posterior hemiblock.
¶
Elevated systolic and diastolic blood pressure were defined using the guidelines from the American Academy of Pediatrics (18) and the American 
College of Cardiology and American Heart Association (19).
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